1Kahn CR. Banting Lecture. Insulin action, diabetogenes, and the cause of type Ⅱ diabetes. Diabetes, 1994,43:1066-1084.
2Kahn BB. Type 2 diabtes: when insulin secretion fails to compensate for insulin resistance. Cell, 1998,92:593-596.
3Warram JH, Martin BC, Krolewski AS, et al. Slow glucose removal rate and hyperinsulinemia precede the development of type Ⅱ diabetes in the offspring of diabetic parents. Ann Intern Med, 1990,113 : 909-915.
4Kahn CR, Chen L, Cohen SE. Unraveling the mechanism of action of thiazolidinediones. J Clin Invest, 2000, 106: 1305-1307.
5Kahn CR, Bruning JC, Michael MD, et al. Knockout mice challenge our concepts of glucose homeostasis and the pathogenesis of diabetes mellitus. J Pediatr Endocrinol Metab,2000,13:1377-1384.
6Bruning JC, Michael MD, Winnay JN, et al. A muscle-specific insulin receptor knockout exhibits features of the metabolic syndrome of NIDDM without altering glucose tolerance. Mol Cell, 1998,2 : 559-569.
7Michael MD, Kulkarni RN, Postic C, et al. Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. Mol Cell, 2000,6: 87-97.
8Ku lkarni RN, Bruning JC, Winnay, JN, et al. Tissue-specific knockout of the insulin receptor in pancreatic beta cells creates an insulin secretory defect similar to that in type 2 diabetes.Cell, 1999,96 : 329-339.
9Bruning, JC, Gautam D, Burks DJ, et al. Role of brain insulin receptor in control of body weight and reproduction. Science,2000,289 : 2122-2125.
10Fujita T, Sugiyama, Y, Taketomi S, et al. Reduction of insulin resistance in obese and/or diabetic animals by 5-[4-(1-methylcyclohexylmethoxy ) benzyl ]-thiazolidine-2, 4-dione(ADD-3878, U-63, 287, ciglitazone), a new antidiabetic agent. Diabetes, 1983,32 : 804-810.
同被引文献9
1Schinner S, Dellas C, Schroder M, Heinlein C A, Chang C, Fischer J, Knepel W. Repression of glucagon gene transcription by peroxisome proliferator-activated receptor γ through inhibition of Pax6 transcriptional activity. J Biol Chem ,2002,277(3): 1941 ～ 1948.
2Malerod L,Sporstol M,Juvet L K,Mousavi A, Gjoen T,Berg T. Hepatic scavenger receptor class B, type I is stimulated by peroxisome proliferator-activated receptor γ and hepatocyte nuclear factor 4 α.Biochem Biophys Res Commun ,2003,305(3) :557 ～ 565.
3Fukunaga Y,Itoh H,Doi K,Tanaka T, Yamashita J,Chun T H,Inoue M, Masatsugu K, Sawada N, Saito T, Hosoda K, Kook H, Ueda M, Nakao K. Thiazolidinediones, peroxisome proliferator-activated receptor gamma agonists, regulate endothelial cell growth and secretion of vasoactive peptides. Atherosclerosis, 2001,158( 1 ): 113 ～ 119.
4Azzazy H M, Highsmith W E Jr. Phage display technology: clinical applications and recent innovations. Clin Biochem, 2002,35 (6): 425 ～445.
5Bernat B, Sun M, Dwyer M, Feldkamp M, Kossiakoff A A. Dissecting the binding energy epitope of a high-affinity variant of human growth hormone: cooperative and additive effects from combining mutations from independently selected phage display mutagenesis libraries. Biochemistry, 2004,43 ( 20 ): 6076 ～ 6084.
6Saltiel A R, New perspectives into the molecular pathogenesis and treatment of type 2 diabetes. Cell ,2001,104(4) :517 ～ 529.
7Gampe R T Jr, Montana V G, Lambert M H, Miller A B, Bledsoe R K, Milburn M V, Kliewer S A, Willson T M, Xu H E. Asymmetry in the PPAR gamma/RXRalpha crystal structure reveals the molecular basis of heterodimerization among nuclear receptors. Mol Cell, 2000,5 ( 3 ): 545 ～ 555.
8Heery D M, Kalkhoven E, Hoare S, Parker M G. A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature, 1997,387(6634) :733 ～ 73621(5):665～672.
